Page last updated: 2024-08-25

picropodophyllin and azd 6244

picropodophyllin has been researched along with azd 6244 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP	1
Chalasani, A; Kraniak, JM; Mattingly, RR; Wallace, MR	1

Studies

Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP

Chalasani, A; Kraniak, JM; Mattingly, RR; Wallace, MR

Other Studies

2 other study(ies) available for picropodophyllin and azd 6244

Article	Year
The target landscape of clinical kinase drugs. Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays	2017
Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Experimental neurology, 2018, Volume: 299, Issue:Pt B Topics: Antineoplastic Agents; Benzimidazoles; Bone Morphogenetic Protein 2; Cell Culture Techniques; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Genes, Neurofibromatosis 1; Genes, Reporter; Humans; Luminescent Proteins; MAP Kinase Kinase 1; Molecular Targeted Therapy; Neurofibroma, Plexiform; Neurofibromatosis 1; Phenotype; Podophyllotoxin; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, IGF Type 1; Red Fluorescent Protein; Schwann Cells; Transduction, Genetic; Tumor Cells, Cultured	2018

Article

Year

The target landscape of clinical kinase drugs.

Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017

Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening.

Experimental neurology, 2018, Volume: 299, Issue:Pt B

Topics: Antineoplastic Agents; Benzimidazoles; Bone Morphogenetic Protein 2; Cell Culture Techniques; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Genes, Neurofibromatosis 1; Genes, Reporter; Humans; Luminescent Proteins; MAP Kinase Kinase 1; Molecular Targeted Therapy; Neurofibroma, Plexiform; Neurofibromatosis 1; Phenotype; Podophyllotoxin; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, IGF Type 1; Red Fluorescent Protein; Schwann Cells; Transduction, Genetic; Tumor Cells, Cultured

2018